$AQST

Aquestive Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Medicinal and Botanical Manufacturing

PRICE

$0.744 โ–ฒ0.541%

Extented Hours

VOLUME

2,409,507

DAY RANGE

0.7 - 0.79

52 WEEK

0.65 - 6.4

Join Discuss about AQST with like-minded investors

profile
@netxpert #marketassasins
recently

for the very first time in a long time my entire portfolio is on fire except CLOV NVDA Apple TSLA AQST AUPH LCID SAVA

75 Replies 10 ๐Ÿ‘ 14 ๐Ÿ”ฅ

profile
@netxpert #marketassasins
recently

@marketjay yes HealthHealth bouncing back. I am watching $AQST do own it earnings 11/03 and FDA approval 12/23. Libervant FDA approval was scheduled for last December but a CRL was issued. FDA received new application fud initial review and accepted the application for PUFDA 12/23

55 Replies 13 ๐Ÿ‘ 13 ๐Ÿ”ฅ

profile
@dros #droscrew
recently

299 $AQST FEB2022 $5 Cs trade 1.6

101 Replies 6 ๐Ÿ‘ 7 ๐Ÿ”ฅ

profile
@dros #droscrew
recently

299 $AQST FEB2022 $5 Cs trade 1.6

137 Replies 12 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@CarlosH-carvan #ivtrades
recently

$AQST penny

89 Replies 6 ๐Ÿ‘ 8 ๐Ÿ”ฅ

profile
@FUZZJP #ivtrades
recently

My last find was $AQST which if you entered would be up even before their PDUFA catalyst.

123 Replies 9 ๐Ÿ‘ 7 ๐Ÿ”ฅ

profile
@DaveDixon #CoreTrader
recently

Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

121 Replies 7 ๐Ÿ‘ 10 ๐Ÿ”ฅ

profile
@DaveDixon #CoreTrader
recently

The pharmaceutical company Aquestive Therapeutics (AQST).

115 Replies 7 ๐Ÿ‘ 13 ๐Ÿ”ฅ

profile
@FUZZJP #ivtrades
recently

$AQST from yesterday is moving

88 Replies 11 ๐Ÿ‘ 14 ๐Ÿ”ฅ

DA
@DanP. #ivtrades
recently

$AQST $7.5 calls a play? @FUZZJP

103 Replies 10 ๐Ÿ‘ 8 ๐Ÿ”ฅ

profile
@FUZZJP #ivtrades
recently

$AQST about to pop

49 Replies 14 ๐Ÿ‘ 10 ๐Ÿ”ฅ

Key Metrics

Market Cap

33.67 M

Beta

1.30

Avg. Volume

1.29 M

Shares Outstanding

44.29 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-02

Next Dividend Date

Company Information

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilmยฎ, and has proven capabilities for drug development and commercialization.

Website:

HQ: ,

Related News